Patents by Inventor Hideya Komatani
Hideya Komatani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10723742Abstract: A compound or a salt thereof represented by Formula (I). An LSD1 inhibitor containing the compound or a salt thereof as an active ingredient. A pharmaceutical composition containing the compound or salt thereof. An antitumor agent containing the compound or a salt thereof as an active ingredient.Type: GrantFiled: November 25, 2016Date of Patent: July 28, 2020Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Satoshi Yamashita, Takahiro Ogawa, Hideya Komatani
-
Publication number: 20180354960Abstract: A compound or a salt thereof represented by Formula (I). An LSD1 inhibitor containing the compound or a salt thereof as an active ingredient. A pharmaceutical composition containing the compound or salt thereof. An antitumor agent containing the compound or a salt thereof as an active ingredient.Type: ApplicationFiled: November 25, 2016Publication date: December 13, 2018Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Satoshi YAMASHITA, Takahiro OGAWA, Hideya KOMATANI
-
Patent number: 9145414Abstract: The present invention provides a compound represented by the following general formula (I) or a salt thereof which has a Syk inhibitory effect (in the formula R1 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; A represents a hydrogen atom, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C2-C6 alkynyl group, an optionally substituted C3-C10 cycloalkyl group, an optionally substituted C6-C14 aromatic hydrocarbon group, an optionally substituted 4- to 10-membered unsaturated heterocyclic group, or an optionally substituted 4- to 10-membered saturated heterocyclic group, or optionally forms a 4- to 10-membered unsaturated heterocyclic ring or a 4- to 10-membered saturated heterocyclic ring together with R1 and the nitrogen atom bonded thereto; R2 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; and B represents an optionally substituted unsaturated heterocyclic group).Type: GrantFiled: September 28, 2012Date of Patent: September 29, 2015Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Toshihiro Sakamoto, Takashi Mita, Kazuaki Shibata, Yoshio Ogino, Hideya Komatani
-
Publication number: 20140343038Abstract: The present invention provides a compound represented by the following general formula (I) or a salt thereof which has a Syk inhibitory effect (in the formula R1 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; A represents a hydrogen atom, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C2-C6 alkynyl group, an optionally substituted C3-C10 cycloalkyl group, an optionally substituted C6-C14 aromatic hydrocarbon group, an optionally substituted 4- to 10-membered unsaturated heterocyclic group, or an optionally substituted 4- to 10-membered saturated heterocyclic group, or optionally forms a 4- to 10-membered unsaturated heterocyclic ring or a 4- to 10-membered saturated heterocyclic ring together with R1 and the nitrogen atom bonded thereto; R2 represents a hydrogen atom or an optionally substituted C1-C6 alkyl group; and B represents an optionally substituted unsaturated heterocyclic group).Type: ApplicationFiled: September 28, 2012Publication date: November 20, 2014Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Toshihiro Sakamoto, Takashi Mita, Kazuaki Shibata, Yoshio Ogino, Hideya Komatani
-
Patent number: 8030327Abstract: The present invention relates to a compound represented by the Formula [I]: Wherein: the A ring is a 5-membered aromatic heterocyclic group containing at least one hetero atom selected from a nitrogen atom, and the like; A1 and A2, are each a nitrogen atom, and the like; X2, X3, X4, and X5 are all carbon atoms, or alternatively any one of X2, X3, X4, and X5 is a nitrogen atom and the rest are all carbon atoms; R1 is a hydrogen atom, or the like; R2, R3, R4, and R5, are each a hydrogen atom, or the like; R6 and R6?, are each a hydrogen atom, and the like; R7 is an aryl group and the like; and R8 is an amino group or a hydroxy group, or a pharmaceutically acceptable salt or ester thereof.Type: GrantFiled: November 7, 2005Date of Patent: October 4, 2011Assignee: MDS K.K.Inventors: Yoshiyuki Sato, Hideki Kurihara, Kaori Kamijo, Yu Onozaki, Toshiaki Tsujino, Tetsuya Sugimoto, Akiko Watanabe, Morihiro Mitsuya, Hideya Komatani
-
Patent number: 7718801Abstract: The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X1, X2, X3, and X4, which may be identical or different, are each C or N, provided that none to two of X1, X2, X3, and X4 is/are N; Y is CH or N; R1, R1?, R2, R2?, R3, R3?, R4, and R4?, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R5 is a hydrogen atom or a methyl group; R6 and R7, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R8 and R8?, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.Type: GrantFiled: August 30, 2005Date of Patent: May 18, 2010Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Mikako Kawamura, Takashi Hashihayata, Satoshi Sunami, Tetsuya Sugimoto, Fuyuki Yamamoto, Yoshiyuki Sato, Kaori Kamijo, Morihiro Mitsuya, Yoshikazu Iwasawa, Hideya Komatani
-
Publication number: 20080103136Abstract: The present invention relates to a compound represented by the Formula [I]: Wherein: the A ring is a 5-membered aromatic heterocyclic group containing at least one hetero atom selected from a nitrogen atom, and the like; A1 and A2, are each a nitrogen atom, and the like; X2, X3, X4, and X5 are all carbon atoms, or alternatively any one of X2, X3, X4, and X5 is a nitrogen atom and the rest are all carbon atoms; R1 is a hydrogen atom, or the like; R2, R3, R4, and R5, are each a hydrogen atom, or the like; R6 and R6?, are each a hydrogen atom, and the like; R7 is an aryl group and the like; and R8 is an amino group or a hydroxy group, or a pharmaceutically acceptable salt or ester thereof.Type: ApplicationFiled: November 7, 2005Publication date: May 1, 2008Inventors: Yoshiyuki Sato, Hideki Kurihara, Kaori Kamijo, Yu Onozaki, Toshiaki Tsujino, Tetsuya Sugimoto, Akiko Watanabe, Morihiro Mitsuya, Hideya Komatani
-
Publication number: 20080070894Abstract: The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein: X1, X2, X3, and X4, which may be identical or different, are each C or N, provided that none to two of X1, X2, X3, and X4 is/are N; Y is CH or N; R1, R1?, R2, R2?, R3, R3?, R4, and R4?, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R5 is a hydrogen atom or a methyl group; R6 and R7, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R8 and R8?, which may be identical or different, are each a hydrogen atom, a lower alkyl group, or the like; R9 is an aryl group or a heteroaryl group which may be substituted; and n is an integer from 1 to 3, and a PLK1 inhibitor or an anticancer agent containing the same.Type: ApplicationFiled: August 30, 2005Publication date: March 20, 2008Inventors: Mikako Kawamura, Takashi Hashihayata, Satoshi Sunami, Tetsuya Sugimoto, Fuyuki Yamamoto, Yoshiyuki Sato, Kaori Kamijo, Morihiro Mitsuya, Yoshikazu Iwasawa, Hideya Komatani
-
Publication number: 20070141619Abstract: The present invention relates to a protein which excretes cancer chemotherapeutic drugs from a cell and which confers drug-resistance on the cell, a DNA encoding the protein, a method for detecting a cell type resistant to cancer chemotherapeutic drugs, a method for screening an inhibitor to overcome the resistance to cancer chemotherapeutic drugs as well as utilizing this knowledge to improve the therapeutic treatment of cancer patients.Type: ApplicationFiled: February 13, 2007Publication date: June 21, 2007Applicant: BANYU PHARMACEUTICAL CO., Ltd.Inventors: Hideya KOMATANI, Yoshikazu Hara, Hidehito Kotani, Rinako Nakagawa
-
Publication number: 20030232362Abstract: The present invention relates to a protein which excretes cancer chemotherapeutic drugs from a cell and which confers drug-resistance on the cell, a DNA encoding the protein, a method for detecting a cell type resistant to cancer chemotherapeutic drugs, a method for screening an inhibitor to overcome the resistance to cancer chemotherapeutic drugs as well as utilizing this knowledge to improve the therapeutic treatment of cancer patients.Type: ApplicationFiled: April 3, 2003Publication date: December 18, 2003Applicant: BANYU PHARMACEUTICAL CO.Inventors: Hideya Komatani, Yoshikazu Hara, Hidehito Kotani, Rinako Nakagawa